MedTrace Logo

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

NCT06017284 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-11-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.

Conditions

  • Pancreatic Cancer Stage IV
  • Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Thalidomide

Thalidomide 100 mg/day, once a day, orally intake at night.

DRUG

Nab paclitaxel

nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.

DRUG

Gemcitabine

gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.

DRUG

Placebo

Placebo, 100 mg/day, once a day, orally intake at night.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Guopei Luo, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06017284 on ClinicalTrials.gov